TinyGemsBreaks Archive

ThursdayApr 18, 2024 2:30 pm

TinyGemsBreaks – Diamond Lake Minerals Inc. (DLMI), BOXABL Partner to Make ‘Quite the Impact’ in Affordable Housing Market

Diamond Lake Minerals (OTC: DLMI), a forward-thinking multi-strategy operating company specializing in digital assets and SEC-registered security tokens, today announced the beginning of its long-term real estate vision and working relationship with Boxabl, Inc. (“BOXABL”), a revolutionary modular home building company. According to the announcement, the partnership with DLMI “further expands the use cases of BOXABL where together they can identify, design and develop beautiful communities, known as BOXABL Villages.” The announcement further noted that DLMI’s leadership and position on the future of finance through security tokens, combined with all traditional means, will create additional unique opportunities for these villages…

ThursdayApr 18, 2024 1:57 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD, a renowned leader in neurodegenerative disease, has joined its scientific advisory board (“SAB”). The announcement noted that the addition reinforces the company’s commitment to advancing its INM-901 program in the treatment of Alzheimer’s disease. Dr. Morgan is the Director of the Alzheimer’s Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. His research interests are Alzheimer’s disease, aging and brain function. “We are privileged to welcome someone of Dr. Morgan’s…

TuesdayApr 16, 2024 3:41 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received approval to begin a new human pilot study. The approval, which was granted by an independent third-party ethics review board, enables Lexaria to move forward with its plan to conduct a GLP-1 study investigating GLP-1 drugs and DehydraTECH(TM). According to the announcement, subject recruitment will begin immediately with the first dosing expected within the next month; the company plans to complete the study this summer. The study will be comprised of two study arms and will include up to nine healthy volunteers. The study is designed to…

TuesdayApr 16, 2024 1:33 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). The reported data continues to demonstrate positive pharmacological effects in the treatment of dry age-related macular degeneration (“AMD”). According to the announcement, in vivo preclinical studies in AMD disease models show that INM-089 delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement. Earlier results showed that INM-089 also preserved retinal function…

MondayApr 15, 2024 3:31 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Concentrating 2024 R&D Plans Mainly on GLP-1 Investigations

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced $3.6 million in gross proceeds from its registered direct offering. “Most notably, Lexaria intends to use the net proceeds from this offering for research and development (‘R&D’) studies and the associated patent and legal costs. It also intends to use the funds for general working capital purposes, important for its current focus on GLP-1 clinical studies for the 2024 calendar year… In 2023, Lexaria laid the groundwork for its GLP-1 clinical studies. The company achieved positive interim and final human pilot study results using a single…

MondayApr 15, 2024 1:37 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently appointed Amy Mahery to its board of directors. “A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas… Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (‘GBM’) treatment, saying,…

ThursdayApr 11, 2024 3:00 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Leveraging Strategic Integrations to Unlock Continued Opportunities

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process and freight logistics, continues to be a marketplace partner with Geotab, a prominent company in the technology and logistics industry. “Fr8Tech announced last September that it had integrated its Fr8App freight-matching platform with Geotab’s open application programming interface (‘API’). According to the company, this integration was intended not only to boost substantially real-time visibility and efficiency for carriers and shippers but also to ensure that clients enjoy added capabilities through the Fr8App platform. The integration exemplifies Fr8App’s continuous improvement and Fr8Tech’s investment…

TuesdayApr 09, 2024 3:43 pm

TinyGemsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Moves Closer to Industrialization of E-Motion(TM) Product

Vision Marine Technologies Inc. (NASDAQ: VMAR), a leader in electric marine propulsion, today announced a groundbreaking achievement in electric outboard propulsion, in collaboration with McLaren Engineering, a division of Linamar Corporation. Aligning with the fast-evolving electric market and the upcoming SAE J1228 outboard compliance standard, Vision Marine has revolutionized the measurement of rated power output with its E-Motion(TM) 180E Electric Powertrain Systems. Vision Marine and McLaren Engineering have developed a sophisticated test cell, designed to meticulously control various critical parameters and provide a comprehensive and precise assessment of the powertrain system under conditions that mimic real-world usage. “We are excited…

TuesdayApr 09, 2024 2:23 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes on $3.2M Public Offering

Flora Growth (NASDAQ: FLGC), a cannabis-focused consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000-plus points of distribution around the world, has closed on an underwritten public offering. The offering, which was comprised of 1.7 million common shares, resulted in $3.23 million in gross proceeds for Flora Growth, before deductions. Flora Growth plans to use the funds from the offering for general corporate and working capital needs. Aegis Capital Corp. acted as the sole book-running manager for the offering, which closed on April 8, 2024. In addition, the company announced that its CEO, Clifford…

MondayApr 08, 2024 3:06 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Streamlines Operations to Focus on Commercial Segment

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that the company has initiated significant cost reduction and consolidation measures, aligning budget to current conditions. Actions are expected to drive an estimated $170 million reduction in Mullen’s operating and investing cash flow expenses over the next 12 months when compared to operating and investing cash flows for the 12 months ended Sept. 30, 2023. The company is making these changes to refine business operations and better align focus on the commercial EV segment that has opportunity to drive near term revenue for Mullen, including projected April sales…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

TinyGemsBreaks